Resumen

SULBARAN, MA  y  LANZA, L. Efecto antiinflamatorio de la Atorvastatina en pacientes con Síndrome Coronario Agudo: Evaluación del perfil lipídico. AVFT [online]. 2004, vol.23, n.2, pp.122-126. ISSN 0798-0264.

The purpose of this study was evaluated the anti-inflammatory effect and the effect on the profile lipidics of the atorvastatine (Tarimyl^®) in patients with acute Coronary Syndrome, were studied patient of both sexes, among 39 and 75 years of age that entered in the Service of Cardiology of the General Hospital of the South «Dr. Pedro Iturbe», located in the Municipality San Francisco of the State Zulia with diagnostic of acute Coronary Syndrome (Unstable angina or Myocardium infarct), during the period understood among the months of March from the 2003 to May of the 2004, to which were divided in two groups, one that received atorvastatine 40 mg. and another group that didn’t receive any estatine and it was considered control. In all the patients were quantified the levels plasmatic of Protein C and Fibrinogen at the beginning, to the week and the month, as well as the lipids levels before and after 4 weeks of treatment. The following results were obtained: The studied population’s age average was located in 58.24 ± 9.39 years in the group control and of 55.31 +/- 9.76 years in the treatment group, the masculine sex prevailed with 58% of the cases in the group control and 62% in the group that Atorvastatina received. The diagnosis of myocardial infart was carried out in 65% of the cases. The average of the levels plasmatics of Protein C to the entrance in the patients treaties with Atorvastatine was located in 3.76 ± 4.5 mg/dl, and after a month in 1.36 ± 1.73 mg/dl. In the patients not tried with Atorvastatine the average of the levels plasmatics of Protein C to the entrance was located in 1.89 ± 2.9 mg/dl, and after a month in 1.91 ± 2.4 mg/dl. The levels of cholesterol were similar to the beginning in both groups presenting a descent in the treated group of 22% (P = 0.005), the levels of LDL-cholesterol diminished in a significant way in the group under treatment 30% (P=0.02). Conclusions: The levels plasmatics of Protein C diminished in 63% in the group tried with Atorvastatina, while in the group control diminished in 1%.

Palabras clave : Protein C; Atorvastatine; Unstable angina; Myocardium infarct; Cholesterol.